• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by OnKure Therapeutics Inc.

    1/21/25 6:38:09 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OKUR alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)


    OnKure Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    75974E103

    (CUSIP Number)


    Jay W. Schmelter
    101 S. Hanley Road, Suite 1850,
    St. Louis, MO, 63105
    (314) 726-6700


    Gloria M. Skigen, Esq.
    Holland & Knight LLP, One Stamford Plaza, 263 Tresser Boulevard Suite 1400
    Stamford, CT, 06901
    (203) 905-4526

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    01/16/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    75974E103


    1 Name of reporting person

    RiverVest Venture Fund III, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    25,400.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    25,400.00
    11Aggregate amount beneficially owned by each reporting person

    25,400.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.20 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    The percentage set forth in line 13 is based on 12,652,890 shares of common stock, par value $0.0001 per share ("Common Stock"), of OnKure Therapeutics, a Delaware corporation (the "Issuer"), outstanding as of November 4, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 7, 2024.


    SCHEDULE 13D

    CUSIP No.
    75974E103


    1 Name of reporting person

    RiverVest Venture Fund III (Ohio), L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,349.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,349.00
    11Aggregate amount beneficially owned by each reporting person

    1,349.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.01 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    The percentage set forth in line 13 is based on 12,652,890 shares of Common Stock, of the Issuer, outstanding as of November 4, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 7, 2024.


    SCHEDULE 13D

    CUSIP No.
    75974E103


    1 Name of reporting person

    RiverVest Venture Partners III (Ohio), LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,349.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,349.00
    11Aggregate amount beneficially owned by each reporting person

    1,349.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.01 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    The amounts set forth in lines 8, 10 and 11 represent 1,349 shares of Common Stock owned by RiverVest Venture Fund III (Ohio), L.P., a Delaware limited partnership ("RiverVest III (Ohio)"). RiverVest Venture Partners III (Ohio), LLC, a Delaware limited liability company ("RiverVest Partners III (Ohio)"), is the general partner of RiverVest III (Ohio). The percentage set forth in line 13 is based on 12,652,890 shares of Common Stock, of the Issuer, outstanding as of November 4, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 7, 2024.


    SCHEDULE 13D

    CUSIP No.
    75974E103


    1 Name of reporting person

    RiverVest Venture Partners III, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    26,749.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    26,749.00
    11Aggregate amount beneficially owned by each reporting person

    26,749.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.21 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    The amounts set forth in lines 8, 10 and 11 represent 25,400 shares of Common Stock owned by RiverVest Venture Fund III, L.P., a Delaware limited partnership ("RiverVest III"), and 1,349 shares of Common Stock owned by RiverVest III (Ohio). RiverVest Venture Partners III, L.P., a Delaware limited partnership ("RiverVest Partners III"), is the general partner of RiverVest III and the sole member of RiverVest Partners III (Ohio), which is the general partner of RiverVest III (Ohio). The percentage set forth in line 13 is based on 12,652,890 shares of Common Stock, of the Issuer, outstanding as of November 4, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 7, 2024.


    SCHEDULE 13D

    CUSIP No.
    75974E103


    1 Name of reporting person

    RiverVest Venture Partners III, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    26,749.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    26,749.00
    11Aggregate amount beneficially owned by each reporting person

    26,749.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.21 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    The amounts set forth in lines 8, 10 and 11 represent 25,400 shares of Common Stock owned by RiverVest III and 1,349 shares of Common Stock owned by RiverVest III (Ohio). RiverVest Venture Partners III, LLC, a Delaware limited liability company, is the general partner of RiverVest Partners III, which is (a) the general partner of RiverVest III and (b) the sole member of RiverVest Partners III (Ohio), which is the general partner of RiverVest III (Ohio). The percentage set forth in line 13 is based on 12,652,890 shares of Common Stock, of the Issuer, outstanding as of November 4, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 7, 2024.


    SCHEDULE 13D

    CUSIP No.
    75974E103


    1 Name of reporting person

    RiverVest Venture Fund IV, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    169,449.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    169,449.00
    11Aggregate amount beneficially owned by each reporting person

    169,449.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    1.34 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    The percentage set forth in line 13 is based on 12,652,890 shares of Common Stock, of the Issuer, outstanding as of November 4, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 7, 2024.


    SCHEDULE 13D

    CUSIP No.
    75974E103


    1 Name of reporting person

    RiverVest Venture Partners IV, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    169,449.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    169,449.00
    11Aggregate amount beneficially owned by each reporting person

    169,449.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    1.34 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    The amounts set forth in lines 8, 10 and 11 represent 169,449 shares of Common Stock owned by RiverVest Venture Fund IV, L.P., a Delaware limited partnership ("RiverVest IV"). RiverVest Venture Partners IV, L.P., a Delaware limited partnership ("RiverVest Partners IV"), is the general partner of RiverVest IV. The percentage set forth in line 13 is based on 12,652,890 shares of Common Stock, of the Issuer, outstanding as of November 4, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 7, 2024.


    SCHEDULE 13D

    CUSIP No.
    75974E103


    1 Name of reporting person

    RiverVest Venture Partners IV, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    169,449.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    169,449.00
    11Aggregate amount beneficially owned by each reporting person

    169,449.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    1.34 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    The amounts set forth in lines 8, 10 and 11 represent 169,449 shares of Common Stock owned by RiverVest IV. RiverVest Venture Partners IV, LLC, a Delaware limited liability company, is the general partner of RiverVest Partners IV, which is the general partner of RiverVest IV. The percentage set forth in line 13 is based on 12,652,890 shares of Common Stock, of the Issuer, outstanding as of November 4, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 7, 2024.


    SCHEDULE 13D

    CUSIP No.
    75974E103


    1 Name of reporting person

    John P. McKearn, Ph.D.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    196,198.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    196,198.00
    11Aggregate amount beneficially owned by each reporting person

    196,198.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    1.55 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    The amounts set forth in lines 8, 10 and 11 represent 25,400 shares of Common Stock owned by RiverVest III, 1,349 shares of Common Stock owned by RiverVest III (Ohio), and 169,449 shares of Common Stock owned by RiverVest IV. Dr. McKearn is a member of RiverVest Venture Partners III, LLC, which is the general partner of RiverVest Partners III. RiverVest Partners III is (a) the general partner of RiverVest III and (b) the sole member of RiverVest Partners III (Ohio), which is the general partner of RiverVest III (Ohio). Dr. McKearn is a member of RiverVest Venture Partners IV, LLC, which is the general partner of RiverVest Partners IV. RiverVest Partners IV is the general partner of RiverVest IV. The percentage set forth in line 13 is based on 12,652,890 shares of Common Stock, of the Issuer, outstanding as of November 4, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 7, 2024.


    SCHEDULE 13D

    CUSIP No.
    75974E103


    1 Name of reporting person

    Jay Schmelter
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    196,198.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    196,198.00
    11Aggregate amount beneficially owned by each reporting person

    196,198.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    1.55 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    The amounts set forth in lines 8, 10 and 11 represent 25,400 shares of Common Stock owned by RiverVest III, 1,349 shares of Common Stock owned by RiverVest III (Ohio), and 169,449 shares of Common Stock owned by RiverVest IV. Mr. Schmelter is a member of RiverVest Venture Partners III, LLC, which is the general partner of RiverVest Partners III. RiverVest Partners III is (a) the general partner of RiverVest III and (b) the sole member of RiverVest Partners III (Ohio), which is the general partner of RiverVest III (Ohio). Mr. Schmelter is a member of RiverVest Venture Partners IV, LLC, which is the general partner of RiverVest Partners IV. RiverVest Partners IV is the general partner of RiverVest IV. The percentage set forth in line 13 is based on 12,652,890 shares of Common Stock, of the Issuer, outstanding as of November 4, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 7, 2024.


    SCHEDULE 13D

    CUSIP No.
    75974E103


    1 Name of reporting person

    Thomas C. Melzer
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    26,749.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    26,749.00
    11Aggregate amount beneficially owned by each reporting person

    26,749.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.21 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    The amounts set forth in lines 8, 10 and 11 represent 25,400 shares of Common Stock owned by RiverVest III and 1,349 shares of Common Stock owned by RiverVest III (Ohio). Mr. Melzer is a member of RiverVest Venture Partners III, LLC, which is the general partner of RiverVest Partners III. RiverVest Partners III is (a) the general partner of RiverVest III and (b) the sole member of RiverVest Partners III (Ohio), which is the general partner of RiverVest III (Ohio). The percentage set forth in line 13 is based on 12,652,890 shares of Common Stock, of the Issuer, outstanding as of November 4, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 7, 2024.


    SCHEDULE 13D

    CUSIP No.
    75974E103


    1 Name of reporting person

    Niall O'Donnell, Ph.D.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    16,595.00
    8Shared Voting Power

    169,449.00
    9Sole Dispositive Power

    16,595.00
    10Shared Dispositive Power

    169,449.00
    11Aggregate amount beneficially owned by each reporting person

    169,449.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    1.34 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    The amounts set forth in lines 7 and 9 represent 16,595 shares of Common Stock options owned by Mr. O'Donnell. The amounts set forth in lines 8, 10 and 11 represent 169,449 shares of Common Stock owned by RiverVest IV. Mr. O'Donnell is a member of RiverVest Venture Partners IV, LLC, which is the general partner of RiverVest Partners IV. RiverVest Partners IV is the general partner of RiverVest IV. The percentage set forth in line 13 is based on 12,652,890 shares of Common Stock, of the Issuer, outstanding as of November 4, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 7, 2024


    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, par value $0.0001 per share
    (b)Name of Issuer:

    OnKure Therapeutics, Inc.
    (c)Address of Issuer's Principal Executive Offices:

    6707 Winchester Circle, Suite 400, Boulder, COLORADO , 80301.
    Item 5.Interest in Securities of the Issuer
    (a)
    The aggregate number and percentage of the shares of Common Stock outstanding beneficially owned by each Reporting Person set forth below and on the cover pages hereof are based on 12,652,890 shares of Common Stock outstanding as of November 4, 2024, as reported in the Issuer's Form 10-Q filed with the SEC on November 7, 2024.
    (b)
    (i) sole power to vote or to direct the vote: see line 7 of cover sheets; (ii) shared power to vote or to direct the vote: see line 8 of cover sheets; (iii) sole power to dispose or to direct the disposition: see line 9 of cover sheets; (iv) shared power to dispose or to direct the disposition: see line 10 of cover sheets. By virtue of the relationships described herein, the Reporting Persons may be deemed to constitute a "group" for purposes of Section 13(d)(3) of the Act. The filing of this Statement shall not be construed as an admission that the Reporting Persons are a group, or have agreed to act as a group. Each Reporting Person expressly disclaims beneficial ownership of the securities reported herein, except to the extent such Reporting Person actually exercises voting or dispositive power with respect to such securities.
    (c)
    Except as set forth herein, none of the Reporting Persons has effected any transactions in shares of the Issuer's Common Stock during the last 60 days.
    (d)
    No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the shares of Common Stock beneficially owned by any of the Reporting Persons
    (e)
    The Reporting Persons ceased to own more than five percent of the outstanding Common Stock on January 16, 2025.
    Item 7.Material to be Filed as Exhibits.
     
    Exhibit A: Joint Filing Agreement, dated April 19, 2021, by and among RiverVest Venture Fund III, L.P., RiverVest Venture Fund III (Ohio), L.P., RiverVest Venture Partners III (Ohio), LLC, RiverVest Venture Partners III, L.P., RiverVest Venture Partners III, LLC, RiverVest Venture Fund IV, L.P., RiverVest Venture Partners IV, L.P., RiverVest Venture Partners IV, LLC, John P. McKearn, Jay Schmelter, Thomas C. Melzer and Niall O'Donnell.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    RiverVest Venture Fund III, L.P.
     
    Signature:By: RiverVest Venture Partners III, L.P., its general partner By: RiverVest Venture Partners III, LLC, its general partner By: /s/ Jay Schmelter
    Name/Title:Jay Schmelter/Member
    Date:01/21/2025
     
    RiverVest Venture Fund III (Ohio), L.P.
     
    Signature:By: RiverVest Venture Partners III (Ohio), LLC, its general partner, as indicated in the signature block that immediately follows By:/s/ Jay Schmelter
    Name/Title:Jay Schmelter/Member
    Date:01/21/2025
     
    RiverVest Venture Partners III (Ohio), LLC
     
    Signature:By: RiverVest Venture Partners III, L.P., its sole member By: RiverVest Venture Partners III, LLC, its general partner By: /s/ Jay Schmelter
    Name/Title:Jay Schmelter/Member
    Date:01/21/2025
     
    RiverVest Venture Partners III, L.P.
     
    Signature:By: RiverVest Venture Partners III, LLC, its general partner By: /s/ Jay Schmelter
    Name/Title:Jay Schmelter/Member
    Date:01/21/2025
     
    RiverVest Venture Partners III, LLC
     
    Signature:By: /s/ Jay Schmelter
    Name/Title:Jay Schmelter/Member
    Date:01/21/2025
     
    RiverVest Venture Fund IV, L.P.
     
    Signature:By: RiverVest Venture Partners IV, L.P., its general partner By: RiverVest Venture Partners IV, LLC, its general partner By: /s/ Jay Schmelter
    Name/Title:Jay Schmelter/Member
    Date:01/21/2025
     
    RiverVest Venture Partners IV, L.P.
     
    Signature:By: RiverVest Venture Partners IV, LLC, its general partner By: /s/ Jay Schmelter
    Name/Title:Jay Schmelter/Member
    Date:01/21/2025
     
    RiverVest Venture Partners IV, LLC
     
    Signature:By: /s/ Jay Schmelter
    Name/Title:Jay Schmelter/Member
    Date:01/21/2025
     
    John P. McKearn, Ph.D.
     
    Signature:/s/ John P. McKearn, Ph.D.
    Name/Title:John P. McKearn, Ph.D.
    Date:01/21/2025
     
    Jay Schmelter
     
    Signature:/s/ Jay Schmelter
    Name/Title:Jay Schmelter
    Date:01/21/2025
     
    Thomas C. Melzer
     
    Signature:/s/ Thomas C. Melzer
    Name/Title:Thomas C. Melzer
    Date:01/21/2025
     
    Niall O'Donnell, Ph.D.
     
    Signature:/s/ Niall O'Donnell, Ph.D.
    Name/Title:Niall O'Donnell, Ph.D.
    Date:01/21/2025
    Get the next $OKUR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OKUR

    DatePrice TargetRatingAnalyst
    4/30/2025Outperform
    Evercore ISI
    12/5/2024$33.00Outperform
    Leerink Partners
    10/10/2024$35.00Outperform
    Oppenheimer
    More analyst ratings

    $OKUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Acorn Bioventures, L.P. bought $2,590,000 worth of shares (1,400,000 units at $1.85) (SEC Form 4)

    4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

    5/19/25 4:43:34 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OKUR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI initiated coverage on OnKure Therapeutics

    Evercore ISI initiated coverage of OnKure Therapeutics with a rating of Outperform

    4/30/25 8:12:14 AM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on OnKure Therapeutics with a new price target

    Leerink Partners initiated coverage of OnKure Therapeutics with a rating of Outperform and set a new price target of $33.00

    12/5/24 8:06:23 AM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on OnKure Therapeutics with a new price target

    Oppenheimer initiated coverage of OnKure Therapeutics with a rating of Outperform and set a new price target of $35.00

    10/10/24 7:48:05 AM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OKUR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update

    -- First patients dosed in triplet expansion arms of the PIKture-01 trial evaluating OKI-219 in combination with fulvestrant and ribociclib, and in combination with trastuzumab and tucatinib in patients with metastatic breast cancer -- Clinical data from OKI-219 PIKture-01 single agent and fulvestrant combination arms are maturing and is now expected to be reported together with initial data from the triplet expansion arms in the first quarter of 2026 -- Significant progress in next-generation PI3Kα pan-mutant inhibitor program; multiple candidates identified - announcement planned for the first quarter of 2026 -- Expansion into Vascular Malformations - additional information to be provid

    11/6/25 4:03:00 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OnKure Therapeutics to Participate in Upcoming Investor Conferences

    BOULDER, Colo., Nov. 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today announced that Nichoals Saccomano, Ph.D., President and Chief Executive Officer, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the Guggenheim Healthcare Innovation Conference, in Boston on Monday, November 10, 2025, at 4:00 p.m. ET. A live audio webcast will be available through this link. A corporate presentation at the Stifel Healthcare Conference, in New York on November 12, 2025, at 4:00 p.m. ET. A live audio webcast

    11/4/25 4:05:00 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update

    -- PIKture-01, a phase 1 clinical trial assessing OKI-219 in patients with advanced solid tumors, including breast cancer, is on track for single agent and fulvestrant combination data in Q4 2025 -- Initiated a new expansion arm of PIKture-01 to evaluate OKI-219 in combination with fulvestrant and ribociclib in HR+ metastatic breast cancer -- Initiated a new expansion arm of PIKture-01 to evaluate OKI-219 in combination with trastuzumab and tucatinib in HER2+ metastatic breast cancer -- Cash position of $83.4M expected to provide cash runway into Q4 2026 BOULDER, Colo., Aug. 12, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutic

    8/12/25 4:05:00 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OKUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mathers Edward T was granted 3,911 shares, increasing direct ownership by 34% to 15,310 units (SEC Form 4)

    4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

    1/2/26 4:16:56 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Manke Isaac was granted 5,258 shares, increasing direct ownership by 34% to 20,583 units (SEC Form 4)

    4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

    1/2/26 4:10:23 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Saccomano Nicholas A sold $258 worth of shares (87 units at $2.97), decreasing direct ownership by 1% to 7,419 units (SEC Form 4)

    4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

    12/23/25 8:09:47 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OKUR
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by OnKure Therapeutics Inc.

    SCHEDULE 13G/A - OnKure Therapeutics, Inc. (0001637715) (Subject)

    1/30/26 2:21:49 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by OnKure Therapeutics Inc.

    SCHEDULE 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)

    11/28/25 8:15:23 AM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by OnKure Therapeutics Inc.

    424B3 - OnKure Therapeutics, Inc. (0001637715) (Filer)

    11/21/25 4:09:22 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OKUR
    Financials

    Live finance-specific insights

    View All

    OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219

    -- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported -- Initial patient data show exposures of OKI-219 exceeding levels associated with robust antitumor activity in preclinical models -- Data support the initiation of Part 1b of PIKture-01 evaluating OKI-219 in combination with fulvestrant; first patients dosed, and initial data are expected in 2H-2025 -- Management to host conference call today, December 10, 2024 at 7:00 a.m. CT BOULDER, Colo., Dec. 10, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medi

    12/10/24 7:00:00 AM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium

    OnKure to host a conference call to review key data presented at SABCS and provide a general corporate update on Friday, December 13, 2024 at 8:00 a.m. ET BOULDER, Colo., Nov. 01, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that two abstracts discussing preliminary clinical data and preclinical data for OKI-219, a potential best-in-class, mutant-selective PI3KαH1047R inhibitor, have been selected for presentation during poster sessions at the 2024 San Antonio Breast Cancer Symposium (SABCS), which is being held virtually and in person from D

    11/1/24 5:30:00 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OKUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by OnKure Therapeutics Inc.

    SC 13G/A - OnKure Therapeutics, Inc. (0001637715) (Subject)

    11/14/24 4:00:05 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by OnKure Therapeutics Inc.

    SC 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)

    11/14/24 10:11:45 AM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by OnKure Therapeutics Inc.

    SC 13G/A - OnKure Therapeutics, Inc. (0001637715) (Subject)

    10/28/24 4:03:06 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OKUR
    Leadership Updates

    Live Leadership Updates

    View All

    OnKure Announces New Date for Upcoming Investor Call

    BOULDER, Colo., Nov. 25, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that posters selected for presentation at the 2024 San Antonio Breast Cancer Symposium (SABCS), including the poster presenting the preliminary data from the Company's first-in-human PIKture-01 trial of OKI-219, will be published to the symposium's virtual meeting platform for registered attendees on December 10th. OnKure will now hold its investor call to review preliminary data from the PIKture-01 study of OKI-219 on Tuesday, December 10, 2024 at 7:00 a.m. CT (8:00 a.m. E

    11/25/24 5:31:00 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care